Evidence map›Paper›PMID 42486903›Full record

ArticleNature biomedical engineering2026

Super homotypic targeting by surface engineering of extracellular vesicles.

Huai-Song Wang, Tianben Ding, Yuhong Liu, Fabio Lisi, Yuqi Zhou, Yaqi Zhao, Xin-Yuan Hu, Zi-Wei Yang, Jing-Lian Su, Mika Hayashi and 23 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Huai-Song Wang *Department of Chemistry, The University of Tokyo, Tokyo, Japan.
Tianben Ding *Department of Chemistry, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0003-0710-2344
Yuhong Liu *Department of Chemistry, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5278-7333
Fabio LisiDepartment of Chemistry, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0003-3597-596X
Yuqi ZhouDepartment of Chemistry, The University of Tokyo, Tokyo, Japan.
Yaqi ZhaoDepartment of Chemistry, The University of Tokyo, Tokyo, Japan.
Xin-Yuan HuDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Zi-Wei YangDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Jing-Lian SuDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Mika HayashiDepartment of Chemistry, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3917-1400
Natsumi Tiffany IshiiDepartment of Chemistry, The University of Tokyo, Tokyo, Japan.
Hiroki MatsumuraDepartment of Chemistry, The University of Tokyo, Tokyo, Japan.
Anel UmirbaevaDepartment of Biological Sciences, Nazarbayev University, Astana, Kazakhstan.ORCID http://orcid.org/0009-0008-0989-3884
Hongwei GuoDepartment of Chemistry, The University of Tokyo, Tokyo, Japan.
Yin-Yu YanDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Fu-Han GaoDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Jia-Jing LiDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Yasutaka KitahamaDepartment of Chemistry, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-6447-2774
Petra PaièDepartment of Physics, Politecnico di Milano, Milano, Italy.
Ayumi TaguchiDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kenbun SoneDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yuka InoueBreast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Takayuki UenoBreast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9080-9377
Abdullah N AlodhaybKing Abdullah Institute for Nanotechnology, King Saud University, Riyadh, Saudi Arabia.ORCID http://orcid.org/0000-0003-0202-8712
Nao NittaCYBO, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9093-9016
Masako NishikawaDepartment of Clinical Laboratory Medicine, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3840-767X
Yutaka YatomiDepartment of Clinical Laboratory Medicine, The University of Tokyo, Tokyo, Japan.
Hiroyuki MatsumuraDepartment of Chemistry, The University of Tokyo, Tokyo, Japan.
Ya DingDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.ORCID http://orcid.org/0000-0001-6214-5641
Masahiro SonoshitaInstitute for Genetic Medicine, Hokkaido University, Sapporo, Japan.ORCID http://orcid.org/0000-0003-2890-336X
Dino Di CarloDepartment of Bioengineering, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-3942-4284
Shiro SuetsuguDivision of Biological Science, Nara Institute of Science and Technology, Ikoma, Japan.ORCID http://orcid.org/0000-0002-4612-0628
Keisuke GodaDepartment of Chemistry, The University of Tokyo, Tokyo, Japan. goda@chem.s.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0001-6302-6038

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Homotypic targeting is the inherent ability of cells to preferentially interact with cells of the same type, a phenomenon seen in cell adhesion, tissue formation and immune responses. However, its potential remains underexploited. Here we report a strategy to substantially enhance homotypic targeting through extracellular vesicles secreted by cells. By engineering the surface of small extracellular vesicles (sEVs) with lanthanides, we amplify specific cell-sEV interactions by more than 25-fold, enabling the selective capture of sEVs by cells of the same lineage even in the presence of excess off-target sEVs. We term this effect 'super homotypic targeting'. Super homotypic targeting provides a means to distinguish sEVs of different origins within highly heterogeneous sEV populations and enables two applications: using cells to detect specific sEVs and using sEVs to detect specific cells, specifically demonstrated here in the context of cancer detection from blood samples. Super homotypic targeting could hold potential for diagnostics, immunotherapy, drug delivery, rejuvenation and tissue engineering.

Identifiers

PMID42486903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.